Streetbeat News

Stock Prices

NRIX

Morgan Stanley has maintained an Equal-Weight rating on Nurix Therapeutics and raised its price target from $11 to $12. This has resulted in Nurix Therapeutics' shares trading higher.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 2:28 pm

BKI

ICE

Black Knight and Intercontinental Exchange have agreed to sell Black Knight's Optimal Blue business to a subsidiary of Constellation Software for $700 million. This has led to a rise in Black Knight's share prices.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 2:27 pm

AMPS

Morgan Stanley has maintained an Overweight rating on Altus Power's stock and increased its price target from $9 to $10. This has resulted in Altus Power's shares trading higher.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 2:27 pm

LEV

Lion Electric Company has entered into subscription agreements with investors for concurrent finance transactions, aiming to raise approximately $142 million. This has led to a rise in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 2:27 pm

STGW

Goldman Sachs has initiated coverage on Stagwell with a Buy rating and a price target of $12. This has led to an increase in Stagwell's stock price.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 2:27 pm

LGND

NOVN

Novan Inc (NOVN) shares are trading lower after Ligand Pharmaceuticals Incorporated (LGND) offered to acquire the company's assets. The deal includes $15 million in cash and up to $15 million in DIP financing. Novan has filed for Chapter 11 reorganization and has entered into a stalking horse acquisition offer with Ligand. The transaction aims to preserve and maximize the value of Novan's commercial business and berdazimer gel development assets. Novan's shares are down 68.1% at $0.20.

Portfolio Pulse from Vandana Singh

July 17, 2023 | 2:25 pm

LIXT

Trading of Lixte Biotechnology shares has resumed.

Portfolio Pulse from Happy Mohamed

July 17, 2023 | 2:22 pm

COYA

Coya Therapeutics Inc (NASDAQ:COYA) reported positive results from an open-label proof-of-concept clinical study for low-dose interleukin 2 (ld IL-2) in patients with Alzheimer's disease. The study showed a significant decrease in the blood levels of proinflammatory cytokines and chemokines, and a statistically significant improvement in cognitive function. The treatment was safe and well tolerated. A Phase 2 study is being conducted at the Houston Methodist Hospital with results anticipated in July 2024. COYA shares are up 2.99% at $4.13.

Portfolio Pulse from Vandana Singh

July 17, 2023 | 2:21 pm

BKI

CNSWF

ICE

Intercontinental Exchange Inc (ICE) and Black Knight Inc (BKI) have agreed to sell Black Knight's Optimal Blue business to a subsidiary of Constellation Software Inc (CNSWF) for $700 million. This is part of efforts to secure regulatory clearance for ICE's proposed acquisition of Black Knight. The divestiture transaction is subject to the closing of ICE's acquisition of Black Knight. ICE shares are trading lower by 1.11% at $116.26 and BKI higher by 14.09% at $69.89.

Portfolio Pulse from Akanksha Bakshi

July 17, 2023 | 2:19 pm

ALNY

REGN

Alnylam Pharmaceuticals announced updated interim results for the Phase 1 study of ALN-APP, an investigational RNAi therapeutic for Alzheimer's disease, developed in collaboration with Regeneron Pharmaceuticals. The single doses of ALN-APP have been well tolerated and showed a rapid and sustained reduction in Alzheimer's-linked proteins. The company's shares soared by 9.62% following the announcement.

Portfolio Pulse from Vandana Singh

July 17, 2023 | 2:18 pm